
Best gluten-free pasta
If you're looking for the best gluten-free pasta, Jovial Penne Rigate Gluten-Free Brown Rice Pasta mimics the traditional texture and flavor of wheat pasta for a reasonable price.
Main ingredients
Gluten-free pasta comes in all shapes and sizes, but the most important thing to note is the ingredient list. Since gluten-free pasta tries to mimic traditional pasta, the challenge comes down to how well other ingredients can hold their shape, deliver a decent flavor and provide a safe meal to those who crave a quality pasta dish.
Without using wheat, rye, barley, couscous, bulgur, and other crossbreeds of those grains, gluten-free pasta can be made from brown rice, white rice, corn, legumes, quinoa, edamame, lentils, or beans. Brown rice pasta is an effective substitute with its mild flavor and chewy texture.
Combinations with multiple ingredients may also include potato starch, tapioca starch, xanthan gum or other gums and starches to provide texture.
Shapes
Many common pasta shapes are available as gluten-free pasta as well. You can find gluten-free spiral, elbow, penne, spaghetti and fettuccine to name a few. Choosing familiar pasta shapes that are gluten-free is a fun way to indulge in your favorite dish without worrying about getting sick from gluten.
Other allergies or sensitivities
Just because a certain pasta is gluten-free doesn't mean it's free of all other allergens. If you're shopping for yourself or someone else with other allergies or food sensitivities, pay attention to the ingredients carefully.
Allergens (or the lack of them) are usually clearly marked on gluten-free packaging. Look for pasta that is free of common allergens, such as milk, soy, fish, shellfish, tree nuts, wheat, eggs and peanuts.
The most important part of gluten-free pasta is its certified lack of gluten. But the best gluten-free pasta also offers a pleasing texture and flavor that rivals its gluten counterparts.
Texture
Gluten-free pasta tends to struggle with texture more than anything else. No matter the ingredients, do not overcook gluten-free pasta. Always cook it al dente and taste test before finishing so you know whether it's done or not.
That said, some ingredients provide a more typical texture than others. Corn, brown rice and white rice pasta tend to hold their form better than a lentil, edamame or legume pasta. It may take a bit of experimenting to find your favorite gluten-free pasta.
Certified gluten-free
The Food and Drug Administration sets strict standards for products certified as gluten-free. This is helpful for people with celiac disease or other conditions who need to completely avoid gluten to avoid potentially life-threatening illnesses.
The FDA sets the main criteria as less than 20 parts per million for any food to be certified as gluten-free. That is the lowest scientifically measurable quantity and is on par with similar guidelines from other countries and organizations.
Organic
Some manufacturers offer the added stamp of approval of certified organic gluten-free pasta. This signifies that no pesticides, synthetic fertilizers or other potentially harmful agrochemicals were used to grow or harvest the ingredients.
Generally, prices for gluten-free pasta range from 50 cents to $1.50 per ounce.
Which type of gluten-free pasta tastes best?
A. This depends on the person eating it. Generally, corn and rice pasta have a mild flavor that's almost imperceptible under any sauce. That offers a plain backdrop for some who want something subtle that mimics plain wheat pasta. Quinoa pasta lends a nutty flavor. Chickpea pasta tastes like chickpeas but is also chewy, making it less sturdy than other ingredients. Additional ingredients or different manufacturers may also change the taste of each type of pasta.
I'm on a low-carb diet. Can I eat gluten-free pasta?
A. Yes, but it depends on the type of gluten-free pasta. Some gluten-free pasta has just as many, if not more, carbs as regular pasta. Legume and edamame pasta are likely low-carb options, as are those made with almond flour. Shirataki noodles are another low-carb option. If you want to avoid unnecessary carbs altogether, try noodles made from zucchini or squash for a vegetable-based dish.
How do I cook gluten-free pasta?
A. Typically, you cook gluten-free pasta the same as you would regular pasta. A few tips may help you achieve the best results:
Top gluten-free pasta
Jovial Penne Rigate Gluten-Free Brown Rice Pasta, Pack of Four
What you need to know: This award-winning pasta cooks surprisingly well and offers great texture and flavor.
What you'll love: It's certified gluten-free and also free of common allergens such as soy, milk, fish, shellfish, wheat, tree nuts, eggs and peanuts. The brown rice pasta comes in six shapes and various multipacks for bargain prices. It holds its shape well when cooked, feels like regular pasta and complements any type of sauce.
What you should consider: It may be on the pricier side if you're cooking for lots of people.
Top gluten-free pasta for the money
Tinkyada Organic Gluten-Free Brown Rice Pasta, Three-shape Variety Bundle
What you need to know: The textured brown rice pasta mimics wheat pasta. The bundle comes with three different types.
What you'll love: The penne, spirals and elbow pasta are organic and gluten-free, made with only brown rice. They cook like wheat pasta and hold their sturdy texture, as long as they're not overcooked. This brand of pasta is especially good for cold pasta salads.
What you should consider: Packages are 12 ounces rather than the typical 16 ounces, so the price may be higher than wheat pasta in the grocery store.
Worth checking out
Banza Chickpea Pasta Variety Pack, Pack of Six
What you need to know: This is a low-carb pasta packed with protein and fiber.
What you'll love: It's a good option for those who need to eat gluten-free and also watch their carb intake. It has a low glycemic index and tastes similar to wheat pasta.
What you should consider: It's not a one-ingredient product, since it also includes tapioca, pea protein and xanthan gum.
BestReviews spends thousands of hours researching, analyzing and testing products to recommend the best picks for most consumers. BestReviews and its newspaper partners may earn a commission if you purchase a product through one of our links.
Distributed by Tribune Content Agency, LLC.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the 'Company' or 'Opus Genetics'), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'We've made significant progress across our pipeline, with multiple clinical and regulatory milestones achieved this quarter,' said George Magrath, M.D., Chief Executive Officer, Opus Genetics. 'Receiving RMAT designation for our OPGx-LCA5 program underscores the strength of our clinical data and the urgent need for effective gene therapies to treat inherited retinal diseases. We are encouraged by the sustained functional vision improvements observed in adult patients in our clinical trial to date and the early signs of efficacy in the pediatric cohort. In parallel, our advancement of OPGx-BEST1 toward the clinic and the nomination of two additional development candidates in partnership with the Retinal Degeneration Fund and the Global RDH12 Alliance highlight the breadth of our IRD pipeline.' 'Beyond gene therapy, the positive readouts from our two Phase 3 Phentolamine trials represent a major step toward our goal of bringing a new treatment option to millions of patients living with vision challenges. With several upcoming key milestones, including new clinical data, a supplemental New Drug Application (sNDA) submission, and the launch of a pivotal study, we remain focused on execution to deliver transformative treatments to patients with significant unmet needs,' Dr. Magrath concluded. Pipeline Updates OPGx-LCA5 – Gene Therapy for Leber Congenital Amaurosis (LCA) The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5, for the treatment of Leber Congenital Amaurosis (LCA) due to genetic variations in the LCA5 gene, signifying the program's potential to address a serious condition and providing a pathway for accelerated development and review. Twelve-month clinical data from adult participants in the Phase 1/2 trial demonstrated sustained improvements in visual function, including visual acuity gains and improved mobility testing scores. This data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May. Initial pediatric data at one-month post-treatment showed vision improvement with no drug-related adverse events; three-month pediatric data is expected to be reported in Q3 2025. OPGx-BEST1 – Gene Therapy for BEST1-Related IRD Preclinical data presented at the American Ophthalmological Society (AOS) in May demonstrated restoration of the retinal pigment epithelium-photoreceptor interface in a canine model of BEST1 using AAV-mediated gene delivery. Investigational New Drug (IND) submission and Phase 1/2 trial initiation remain on track for the second half of 2025. OPGx-RDH12 and OPGx-MERTK – Advancing with Non-Dilutive Support Partnership with the Global RDH12 Alliance provides up to $1.6 million in non-dilutive funding to accelerate development of OPGx-RDH12 for Leber congenital amaurosis (RDH12-LCA). Non-dilutive funding up to $2 million received from the Retinal Degeneration Fund to advance OPGx-MERTK, targeting retinitis pigmentosa caused by MERTK mutations. Preclinical OPGx-MERTK data presented at the American Society of Gene & Cell Therapy (ASGCT) in May showed preservation of retinal function in animal models. Phentolamine Ophthalmic Solution 0.75% – Advancing Toward sNDA Submissions VEGA-3 Phase 3 trial met its primary and multiple secondary endpoints in presbyopia, with 27.2% of treated patients achieving a ≥15-letter gain in near visual acuity (vs. 11.5% on placebo, p<0.0001) and favorable participant reported outcomes and safety profile. LYNX-2 Phase 3 trial met its primary and multiple secondary endpoints in keratorefractive patients with night vision disturbances. Patients showed statistically significant gains in mesopic low contrast vision and improvements in night-driving related symptoms. sNDA submission for presbyopia indication planned for the second half of 2025. LYNX-3 Phase 3 trial expected to initiate enrollment in the second half of 2025 targeting reduced low light vision and nighttime visual disturbances. Additional Medical Meeting Presentations Virtual reality-guided functional testing to support meaningful clinical endpoints in IRD trials was presented at the Retinal Imaging Biomarkers Summit. Upcoming Expected Data Readouts and Program Advancements Report three-month pediatric data from OPGx-LCA5 Phase 1/2 trial in Q3 2025. Initiate enrollment in Phase 1/2 trial for OPGx-BEST1 in H2 2025. Submit Phentolamine sNDA for presbyopia in H2 2025. Initiate enrollment in Phentolamine LYNX-3 Phase 3 trial in H2 2025. Financial Results for the Second Quarter Ended June 30, 2025 Cash Position: As of June 30, 2025, Opus Genetics had cash and cash equivalents of $32.4 million. Based on current operating plans, the Company expects its existing cash resources will fund operations into the second half of 2026. Revenue: License and collaboration revenue totaled $2.9 million for the second quarter of 2025, compared to $1.1 million in the same period in 2024. Revenue in both periods was driven by the Company's collaboration with Viatris, Inc., primarily from reimbursement of R&D services. General and Administrative (G&A) Expenses: G&A expenses were $5.8 million for the second quarter of 2025, compared to $3.4 million for the same period in 2024. The increase was mainly due to higher costs associated with legal and patent-related expenses, payroll, and business development activities. G&A expenses included $0.6 million and $0.5 million in stock-based compensation in the second quarters of 2025 and 2024, respectively. Research and Development (R&D) Expenses: R&D expenses were $6.0 million for the second quarter of 2025, compared to $6.1 million in the prior-year period. The slight decrease was primarily due to lower manufacturing and consulting costs, partially offset by increased clinical trial, toxicology, and payroll-related expenses. R&D expenses related to Phentolamine Ophthalmic Solution 0.75% were fully reimbursed under the Viatris License Agreement. Stock-based compensation within R&D expenses was $0.3 million in both periods. Net Loss: Net loss for the second quarter of 2025 was $7.4 million, or $(0.12) per basic and diluted share, compared to a net loss of $7.8 million, or $(0.30) per basic and diluted share, for the second quarter of 2024. SEC Filing: Additional details on the Company's financial results will be available in its Quarterly Report on Form 10-Q for the period ended June 30, 2025, to be filed with the U.S. Securities and Exchange Commission (SEC). About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway, the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading 'Risk Factors' included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Contacts: InvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@ MediaKimberly HaKKH Opus Genetics, Consolidated Balance Sheets(in thousands, except share amounts and par value) As of June 30, December 31, 2025 2024 Assets (Unaudited) Current assets: Cash and cash equivalents $ 32,429 $ 30,321 Accounts receivable 3,399 3,563 Contract assets and unbilled receivables 1,178 2,209 Prepaids and other current assets 1,433 515 Short-term investments — 2 Total current assets 38,439 36,610 Property and equipment, net 226 252 Total assets $ 38,665 $ 36,862 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,465 $ 3,148 Accrued expenses and other liabilities 6,927 8,147 Warrant liabilities 11,800 — Total current liabilities 20,192 11,295 Long-term funding agreement, related party 1,000 — Total liabilities 21,192 11,295 Commitments and contingencies Series A preferred stock, par value $0.0001; 14,146 shares were designated as of June 30, 2025 and December 31, 2024; zero and 14,145.374 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. — 18,843 Stockholders' equity: Preferred stock, par value $0.0001; 9,985,854 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024. — — Common stock, par value $0.0001; 125,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 59,908,055 and 31,574,657 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 6 3 Additional paid-in capital 172,079 145,719 Accumulated deficit (154,612 ) (138,998 ) Total stockholders' equity 17,473 6,724 Total liabilities, series A preferred stock and stockholders' equity $ 38,665 $ 36,862 Opus Genetics, Consolidated Statements of Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 License and collaborations revenue $ 2,882 $ 1,112 $ 7,252 $ 2,823 Operating expenses: General and administrative 5,766 3,354 12,112 8,024 Research and development 6,022 6,086 13,975 10,835 Total operating expenses 11,788 9,440 26,087 18,859 Loss from operations (8,906 ) (8,328 ) (18,835 ) (16,036 ) Fair value change in warrant and other derivative liabilities 917 — 3,722 — Financing costs 35 — (1,337 ) — Other income, net 534 563 836 1,165 Loss before income taxes (7,420 ) (7,765 ) (15,614 ) (14,871 ) Benefit (provision) for income taxes — — — — Net loss (7,420 ) (7,765 ) (15,614 ) (14,871 ) Other comprehensive loss, net of tax — — Comprehensive loss $ (7,420 ) $ (7,765 ) $ (15,614 ) $ (14,871 ) Net loss per share: Basic and diluted $ (0.12 ) $ (0.30 ) $ (0.32 ) $ (0.59 ) Number of shares used in per share calculations: Basic and diluted 63,376,392 25,827,265 48,712,124 25,175,596 Source: Opus Genetics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
an hour ago
- Business Wire
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the second quarter 2025 ended June 30, 2025, and provided an update on its portfolio of AI-driven drug candidates and AI platform, RADR®. ' This quarter we observed complete responses in patients across two of our clinical trials, delivering meaningful patient benefit and providing further validation of both the mechanisms and therapeutic potential of our drug candidates, ' said Panna Sharma, CEO & President of Lantern Pharma. Simultaneously, our team is transforming our AI platform into functional, accessible modules for the broader oncology community. These parallel advances mark a pivotal inflection point in our clinical and technological evolution, reinforcing our fiscally disciplined, AI-driven approach to addressing critical unmet patient needs with a clear pathway to commercialization and value creation. ' Clinical Pipeline Developments LP-184: Successful Completion of Enrollment for Phase 1a & Advancing Toward Phase 1b/2 Studies Lantern successfully completed enrollment of its LP-184 Phase 1a first-in-human trial with 65 patients across multiple solid tumor indications. The trial established both the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), positioning LP-184 for advancement of planned Phase 1b/2 studies in indications with large multi-billion dollar annual market potential, including recurrent TNBC and recurrent bladder cancer. LP-184 has received Fast Track Designations from the FDA for both glioblastoma multiforme (GBM) and triple negative breast cancer (TNBC), along with four Rare Pediatric Disease Designations for hepatoblastoma, rhabdomyosarcoma, malignant rhabdoid tumors, and atypical teratoid rhabdoid tumors (ATRT). Through its wholly-owned subsidiary Starlight Therapeutics, Lantern is developing LP-184 as STAR-001 for central nervous system cancers. During the quarter, Lantern announced findings from independent research conducted at Johns Hopkins validating Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and support planned pediatric clinical trials. The data demonstrated that LP-184, a next-generation acylfulvene clinical-stage drug candidate, significantly extended survival in mouse models of ATRT. In the CHLA06 model, median survival increased from 20 days in the control group to 89 days in the LP-184 treatment group, representing a 345% improvement (p<0.0001). In the BT37 model, median survival increased from 68 days to 98 days (p=0.0422). LP-184 is a next-generation acylfulvene drug candidate, a synthetic small molecule belonging to a class of naturally-derived anti-cancer agents. LP-184 works by preferentially damaging DNA in cancer cells that overexpress specific biomarkers or that harbor mutations in DNA damage repair pathways. LP-184 is the product of years of research, including insights from RADR ®, Lantern's proprietary AI platform that leverages over 200 billion oncology-focused data points. LP-184 is a prodrug that is converted to its bioactive form inside the cancer cell by PTGR1 (prostaglandin reductase 1), an enzyme that is overexpressed in certain cancers. Once activated, LP-184 creates cytotoxic metabolites that form adducts with DNA, leading to irreparable DNA damage and ultimately tumor cell death. LP-300 HARMONIC™ Trial: Complete Response Observed Demonstrating Clinical Activity & Successful Completion of Enrollment in Japan The Phase 2 HARMONIC™ trial continues to advance with enrollment across the United States and expansion sites in Asia. A remarkable complete response was observed in a 70-year-old never-smoker patient with advanced NSCLC who had exhausted three prior treatment regimens. This outcome builds on previously reported data showing an 86% clinical benefit rate and 43% objective response rate in the initial safety lead-in cohort. Additionally the Phase 2 HARMONIC™ trial made advancements in Asia with completion of the Japanese cohort of 10 patients. Multiple centers in Japan participated in the clinical trial including The National Cancer Center Tokyo. The study is strategically positioned in regions with high prevalence of never-smoker lung cancer patients, with active sites in Taiwan where over 40% of new lung cancer diagnoses occur in never-smokers. Additional clinical data and findings are anticipated in September 2025, including initial safety and response evaluations from the Asian expansion cohort. The treatment of never-smokers with NSCLC represents a market opportunity estimated at over $4 billion annually. There are no approved therapies specifically targeted at the treatment of never-smokers with NSCLC currently. Lantern is actively exploring collaboration and partnering opportunities to maximize LP-300's commercial potential in multiple geographies. LP-284: Phase 1a Clinical Trial in Refractory Lymphoma Observed a Complete Response LP-284 exhibited remarkable clinical activity in a heavily pretreated 41-year-old patient with aggressive Grade 3 diffuse large B-cell lymphoma (DLBCL). Following failure of standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab), the patient achieved complete metabolic response with non-avid lesions after completing just two doses of LP-284. This represents the first complete response observed with LP-284. The complete response provides support to the mechanistic rationale and the potential for further future clinical activity in one of the most therapeutically challenging hematological malignancies. Lantern believes that this supports LP-284's synthetic lethal mechanism and potential paradigm-shifting role in treating refractory aggressive lymphomas. The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations. Intellectual Property Advancements Lantern significantly strengthened its global intellectual property portfolio during the second quarter with two major patent developments: European Patent Allowance for LP-284: The European Patent Office (EPO) issued a notice of allowance for a composition of matter patent covering LP-284, expected to be granted with exclusivity through early 2039. This EU patent complements existing composition of matter patents granted in the U.S. (April 2023) and Japan (June 2024), with additional patent allowances in India and Mexico, and applications pending in China, Australia, Canada, and Korea. This expanding international IP portfolio positions LP-284 for global commercialization and strategic partnerships. Blood-Brain Barrier Prediction Patent Application: Lantern announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability, which received a favorable PCT search report indicating no significant prior art. The technology powering predictBBB™ demonstrates exceptional performance, processing up to 100,000 molecules per hour with industry-leading accuracy. Lantern's AI algorithms currently hold five of the top eleven positions on the Therapeutic Data Commons Leaderboard. The PCT application, if granted, will enable multi-country patent protection for 20 years from the filing date. RADR ® AI Platform Enhancements Lantern continues to expand the capabilities of its RADR ® platform, which now leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms. Key enhancements this quarter include: Module Public Launch: The public release of an AI module for predicting blood-brain barrier permeability with 94% prediction accuracy, 95% sensitivity and 89% specificity. This addresses a critical pharmaceutical development challenge where only 2-6% of small-molecule drugs can successfully cross the blood-brain barrier. Drug Combination Prediction Module: An innovative AI-powered module to improve prediction of synergistic cancer drug combinations, with framework and analytics based on peer-reviewed research. The module focuses initially on DNA damaging agents and DNA repair inhibitors, aimed at a market opportunity where approximately $50 billion is spent annually on the development of combination therapies for cancer. The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors. The framework and foundational data for the module was published in a peer-reviewed study published in Frontiers in Oncology, ' Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review '. The company plans to make select RADR ® modules available to the broader scientific and research community, fostering collaborative, open-source innovation in oncology drug development while creating potential new revenue streams. Financial Results for Second Quarter 2025 Balance Sheet: Cash, cash equivalents, and marketable securities were approximately $15.9 million as of June 30, 2025, compared to approximately $24.0 million as of December 31, 2024. The company believes that its existing cash, cash equivalents, and marketable securities as of June 30, 2025 and anticipated expenditures will enable funding of operating expenses and capital expenditure requirements at least into June 2026. Research and Development Expenses: R&D expenses were approximately $3.1 million for the quarter ended June 30, 2025, compared to approximately $3.9 million for the quarter ended June 30, 2024, reflecting continued disciplined cost management while advancing multiple clinical programs. General and Administrative Expenses: G&A expenses were approximately $1.6 million for the quarter ended June 30, 2025, compared to approximately $1.5 million for the quarter ended June 30, 2024. Net Loss: Net loss was approximately $4.33 million (or $0.40 per share) for the quarter ended June 30, 2025, compared to a net loss of approximately $4.96 million (or $0.46 per share) for the quarter ended June 30, 2024. Capitalization: As of June 30, 2025, the Company had 10,784,725 shares of common stock outstanding, and options to purchase 1,239,766 shares of common stock at a weighted average exercise price of $5.72 per share were outstanding. There were no outstanding warrants as of June 30, 2025. Quarterly Earnings Calls: Lantern has determined not to host a quarterly earnings call at the present time given the concentration of resources required for a live video based webinar style call. In addition to quarterly press releases with earnings information, and more frequent updates regarding the progress of our portfolio and platform, we plan to focus our resources on other distribution channels that we believe will be more effective in conveying information to stockholders, including webinars, digital media resources and broader social media channels. June 30, 2025 December 31, 2024 (Unaudited) CURRENT ASSETS Cash and cash equivalents $ 6,061,408 $ 7,511,079 Marketable securities 9,840,366 16,501,984 Prepaid expenses & other current assets 1,299,016 1,234,566 Total current assets 17,200,790 25,247,629 Property and equipment, net 39,524 47,440 Operating lease right-of-use assets 143,240 239,985 Other assets 36,738 36,738 TOTAL ASSETS $ 17,420,292 $ 25,571,792 CURRENT LIABILITIES Accounts payable and accrued expenses $ 4,752,848 $ 4,140,361 Operating lease liabilities, current 131,515 190,814 Total current liabilities 4,884,363 4,331,175 Operating lease liabilities, net of current portion 13,524 52,843 TOTAL LIABILITIES 4,897,887 4,384,018 COMMITMENTS AND CONTINGENCIES (NOTE 4) STOCKHOLDERS' EQUITY Preferred Stock (1,000,000 authorized at June 30, 2025 and December 31, 2024; $.0001 par value) (Zero shares issued and outstanding at June 30, 2025 and December 31, 2024) - - Common Stock (25,000,000 authorized at June 30, 2025 and December 31, 2024; $.0001 par value) (10,784,725 shares issued and outstanding at June 30, 2025 and December 31, 2024) 1,078 1,078 Additional paid-in capital 97,366,699 97,058,323 Accumulated other comprehensive income 48,043 153,990 Accumulated deficit (84,893,415 ) (76,025,617 ) Total stockholders' equity 12,522,405 21,187,774 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ $ 25,571,792 Expand About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. Lantern Pharma Disclosure Channels to Disseminate Information: Lantern Pharma's investors and others should note that we announce material information to the public about our company and its technologies, clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma's website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations above as such information could be deemed to be material information. Please note that this list may be updated from time to time.


Fast Company
an hour ago
- Fast Company
FDA warns one of summer's biggest viral beauty hits may not be safe
If your summer skincare looks more like dessert than SPF, the FDA has a message: put down the whipped cream canister — especially if it's actually sunscreen. On Monday, the agency dropped an unusually beachy buzzkill, warning that mousse-style sunscreens — the viral, fluffy-textured formulas all over TikTok — might not protect you as promised. Even worse? Their ice-cream-topping aesthetic could tempt someone to take a taste. And yes, that's as bad of an idea as it sounds. 'Beware of sunscreen products in mousse form because they might not be effective,' the agency wrote on X. 'Some mousse sunscreen products resemble whipped cream containers and may put consumers at risk if ingested.' The FDA's social media statement was accompanied by a flurry of official warnings issued to companies making mousse-style sunscreens, which have taken off thanks to TikTok trends and influencer campaigns. On TikTok, some videos joke about mousse sunscreen's resemblance to whipped cream by pretending to ingest it. Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters The warnings were issued to five sunscreen companies: Supergoop, Vacation, TiZO, Kalani and K & Care Organics. Beware of sunscreen products in mousse form because they might not be effective. The FDA issued five warning letters to companies marketing sunscreen products in mousse form: — FDA Drug Information (@FDA_Drug_Info) August 12, 2025 In the letters, the FDA states that the brands' mousse sunscreens don't comply with its guidelines and haven't been approved to be marketed in mousse form. According to the FDA, sunscreens in forms 'other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder' need an additional authorization to be marketed as effective sunscreen. 'As previously stated, there are no FDA-approved applications in effect for your drug products,' the agency states. The FDA gave the sunscreen brands 15 days to reply or pursue compliance with the concerns in the letter, which was dated back to August 6. The FDA went further with the viral mousse sunscreen brand Vacation, pointing to 'misbranding' concerns with some of the company's packaging. Vacation's Classic Whip sunscreen comes in a red and white canister that's designed to look almost exactly like a can of whipped cream – a marketing flourish that sent its mousse sunscreens viral. 'Specifically, your sunscreens are presented in metal canisters… that outputs a star-shaped foam and have a strong overall resemblance to the metal canisters ordinarily used to package whipped cream products and similar dessert toppings,' the FDA wrote, adding that selling products classified as drugs in food container lookalikes increases the risk of accidental ingestion. What's the deal with the mousse? While traditional lotion, stick and spray sunscreens have occupied drug store shelves for years, mousse-style sunscreens only exploded onto the scene recently. Accelerated by TikTok posts of influencers slathering themselves in what looks like Reddi-wip, Vacation quickly enjoyed its social media-powered moment in the sun. advertisement 'At Supergoop! we remain committed to innovation in sun care and the highest standards of product efficacy and safety,' the company told Fast Company in a statement. 'The recent communication from the FDA regarding our PLAY SPF 50 Body Mousse is focused on product labeling and has nothing to do with its safety, effectiveness, or formula. We are working closely with the FDA to resolve this matter as we continue to uphold the high standards our consumers expect from us.'